We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The study’s authors “erroneously state that FDA abandoned efforts to evaluate the impact of the ER/long-acting REMS program on prescriber behavior and patient outcomes,” the agency said. Read More
Allergan and Ironwood Pharmaceuticals reached a settlement with Sandoz to resolve patent litigation over Sandoz’s planned generic versions of their co-developed irritable bowel syndrome treatment Linzess. Read More
The drug was originally approved in October 2017 as the first extended-release intra-articular therapy for patients with osteoarthritis-related knee pain. Read More
A group of consumers filed a class action suit against Pfizer, alleging that the company knew or should have known that its over-the-counter heartburn drug Zantac (ranitidine) was contaminated with dangerous levels of NDMA and unsafe for consumption. Read More
Allergan reached a $300 million settlement to resolve a class action lawsuit over the oral contraceptives Loestrin 24 Fe (norethindrone acetate, ethinyl estradiol, and ferrous fumarate) and Minastrin 24 Fe (norethindrone acetate and ethinyl estradiol/ferrous fumarate). Read More